PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Tsiverioti, C.A.* ; Gottschlich, A.* ; Trefny, M.P.* ; Theurich, S.* ; Anders, H.J.* ; Kroiss, M.* ; Kobold, S.

Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.

Biol. Chem., DOI: 10.1515/hsz-2023-0317 (2024)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Chimeric antigen receptor (CAR)-T cell therapy has led to remarkable clinical outcomes in the treatment of hematological malignancies. However, challenges remain, such as limited infiltration into solid tumors, inadequate persistence, systemic toxicities, and manufacturing insufficiencies. The use of alternative cell sources for CAR-based therapies, such as natural killer cells (NK), macrophages (MΦ), invariant Natural Killer T (iNKT) cells, γδT cells, neutrophils, and induced pluripotent stem cells (iPSC), has emerged as a promising avenue. By harnessing these cells' inherent cytotoxic mechanisms and incorporating CAR technology, common CAR-T cell-related limitations can be effectively mitigated. We herein present an overview of the tumoricidal mechanisms, CAR designs, and manufacturing processes of CAR-NK cells, CAR-MΦ, CAR-iNKT cells, CAR-γδT cells, CAR-neutrophils, and iPSC-derived CAR-cells, outlining the advantages, limitations, and potential solutions of these therapeutic strategies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
2.900
0.000
1
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Car-nk Cells ; Car-t Cells ; Car-inkt Cells ; Car-macrophages ; Car-neutrophils ; Car-γδt cells; Chimeric-antigen-receptor; Natural-killer-cells; Pluripotent Stem-cells; V-alpha-24-invariant Nkt Cells; Acute Myeloid-leukemia; In-vivo Expansion; Phase-i; Dendritic Cells; Adoptive Immunotherapy; Antitumor-activity
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 1431-6730
e-ISSN 1437-4315
Zeitschrift Biological Chemistry
Verlag de Gruyter
Verlagsort Genthiner Strasse 13, D-10785 Berlin, Germany
Begutachtungsstatus Peer reviewed
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-522100-001
Förderungen Go-Bio-Initiative
DOI 10.1515/hsz-2023-0317
WOS ID 001227430400001
PubMed ID 38766710
Erfassungsdatum 2024-06-14
[➜Korrektur melden]